Medicines | European Medicines Agency

Medicines

For help on how to get the results you want, see our search tips.

Search results

Categories

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Product number

Patient safety

Authorisation status

ATC code

Marketing authorisation date

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

Medicine type

Therapeutic area

Last updated

First published

6 results

Sort by

List item

Human medicine European public assessment report (EPAR): Arepanrix

split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 23/03/2010, , Revision: 1, Withdrawn, Last updated: 25/10/2011
List item

Human medicine European public assessment report (EPAR): Daklinza

daclatasvir dihydrochloride, Hepatitis C, Chronic
Date of authorisation: 22/08/2014, , Revision: 15, Withdrawn, Last updated: 30/08/2019
List item

Human medicine European public assessment report (EPAR): Humenza

split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 08/06/2010, , Withdrawn, Last updated: 30/06/2011
List item

Human medicine European public assessment report (EPAR): Lartruvo

Olaratumab, Sarcoma
Date of authorisation: 09/11/2016, , , , , Revision: 3, Withdrawn, Last updated: 02/09/2019
List item

Human medicine European public assessment report (EPAR): Prepandrix (updated)

A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2), Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 14/05/2008, , Revision: 13, Withdrawn, Last updated: 23/02/2021
List item

Human medicine European public assessment report (EPAR): Zalmoxis

Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
Date of authorisation: 18/08/2016, , Revision: 1, Withdrawn, Last updated: 14/02/2020